Ixekizumab and Ustekinumab Efficacy in Nail Psoriasis in Patients with Moderate-to-Severe Psoriasis: 52-Week Results from a Phase 3, Head-to-Head Study (IXORA-S)
posted on 2020-05-11, 10:17authored byNorman Wasel, Diamant Thaçi, Lars E. French, Curdin Conrad, Yves Dutronc, Gaia Gallo, Lovisa Berggren, Jean-Philippe Lacour
The above Summary Slide represents the opinions of
the authors. For a full list of declarations, including funding and author
disclosure statements, please see the full text online (see “read the
peer-reviewed publication” opposite).